UC Causal Mechanism Digest 002 — Why UC Starts Distally / Proctitis First

Why this digest matters

Paul’s disease expression is primarily proctitis/distal UC, and the central theory needs to explain why UC commonly starts in the rectum rather than treating the location as incidental.

This batch focused on literature around:

• the clinical fact that UC typically begins in the rectum and extends proximally;
• rectal/proctitis symptoms including mucus, bleeding, urgency, tenesmus, constipation, and rectal pain;
• mucus barrier failure and bacteria reaching the epithelial surface;
• phosphatidylcholine thinning toward the rectum;
• fecal stream, short-chain fatty acids, and stool/luminal-contact effects;
• distal microbiome/metabolite gradients.

Bottom line for the central theory

The best current explanation is not a single-cause answer like “the rectum is autoimmune.” It is a stacked distal vulnerability model:

Rectum/distal colon = high microbial load + fecal stasis/contact + local mucus/PC vulnerability
        ↓
If mucus barrier becomes penetrable or PC-poor, bacteria/metabolites reach epithelium
        ↓
Rectal mucosa responds with mucus, urgency/tenesmus, altered motility/constipation
        ↓
Persistent contact + impaired epithelial energy/redox repair → bleeding and inflammation
        ↓
Disease may extend proximally if upstream mucus/barrier/metabolic defenses fail

Source-by-source digest

1. UC clinically starts in the rectum and extends proximally

Sources:

• Danese & Fiocchi. Lancet 2012. PMID: 22914296.
• Ungaro et al./classification review. Autoimmunity Reviews 2014. PMID: 24424198.
• Comprehensive UC review. Disease-a-Month 2019. PMID: 30837080.

Key extracted points:

• UC is described as chronic mucosal inflammation that starts in the rectum and usually extends proximally in a continuous pattern.
• Classic UC affects the colon in a retrograde and continuous fashion from the rectum.
• Disease extent is commonly classified as proctitis, left-sided colitis, or pancolitis.
• Rectal bleeding, mucus, urgency, tenesmus, diarrhea and/or constipation are classic distal/proctitis symptoms.

Central-theory implication:

• Paul’s proctitis-first pattern is not unusual; it is the canonical UC pattern.
• The core question becomes: what makes the rectum the first vulnerable site?

2. Ulcerative proctitis is a local rectal disease state with overlapping etiologies

Sources:

• “Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis.” Inflammatory Bowel Diseases 2015. PMID: 25687266.
• “Diagnosis and treatment of ulcerative proctitis.” Journal of Clinical Gastroenterology 2004. PMID: 15365396.
• “Proctitis: An Approach to the Symptomatic Patient.” Medical Clinics of North America 2024. PMID: 38331484.

Key extracted points:

• Chronic proctitis means persistent/relapsing inflammation of the rectum and can arise from multiple etiologies: ulcerative proctitis, radiation injury, diversion proctitis, infection/STIs, medications, ischemia, etc.
• Symptoms can include rectal bleeding, urgency, tenesmus, diarrhea or constipation, and rectal pain.
• The diagnosis is endoscopic/histologic and differential diagnosis matters.

Central-theory implication:

• Rectal inflammation is a shared endpoint of multiple insults, which supports a local-vulnerability model.
• For Paul, this reinforces the need to separate:
  • UC/proctitis immune-barrier disease;
  • infection/STI/infectious proctitis when relevant;
  • ischemic/medication/radiation-type injury if history ever fits;
  • pelvic floor/constipation/contact-time amplifiers.

Safety note:

• This does not imply Paul’s proctitis is infectious; it means rectal-local symptoms require careful differential diagnosis if presentation changes.

3. Active UC mucus becomes penetrable; bacteria can contact epithelium

Sources:

• Johansson et al. Gut 2014. “Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis.” PMID: 23426893. Full extract: https://gut.bmj.com/content/63/2/281
• “Mucus layers in inflammatory bowel disease.” Inflammatory Bowel Diseases 2014. PMID: 25025717.
• “Mucus and the goblet cell.” Digestive Diseases 2013. PMID: 24246979.
• Muc2-deficient mouse / active UC features. PMID: 24945909.

Key extracted points:

• Healthy sigmoid colon has an inner MUC2-rich mucus layer that normally keeps bacteria away from epithelial cells.
• In active UC, this normally protective mucus layer becomes highly penetrable, allowing bacteria or bacteria-sized particles to reach epithelium.
• Many mouse colitis models show the same pattern: bacteria in contact with epithelium.
• In most UC patients in remission, the mucus layer looks more impenetrable like controls, but some remission patients still have penetrable mucus.
• MUC2/goblet-cell biology is central: loss or dysfunction of the mucus layer allows bacteria into crypts/epithelial contact and can produce colitis-like disease in models.

Central-theory implication:

• This is one of the strongest pillars for the central theory.
• It explains why symptoms may begin with mucus: mucus barrier failure/compensatory secretion may precede bleeding.
• It connects local barrier failure to immune activation without requiring the immune system to be the first cause.

4. Phosphatidylcholine may thin toward the rectum; lowest PC reserve could explain rectal-first vulnerability

Source: “Mucosal protection by phosphatidylcholine as new therapeutic concept in ulcerative colitis.” PMID: 23585269.

Key extracted abstract claims:

• Colonic mucus is a first barrier against invasion of commensal bacteria in stool.
• Phosphatidylcholine (PC) represents more than 90% of mucus phospholipids.
• PC helps form a hydrophobic surface over hydrated mucus gel to prevent bacterial invasion.
• In UC, mucus PC content is reportedly reduced by ~70% irrespective of inflammation state.
• PC is described as mainly secreted by ileal mucosa and moving distally through the colon.
• The abstract states PC content gradually thins toward the rectum, with the lowest PC content at the rectum.

Central-theory implication:

• This is the cleanest mechanism found so far for why UC often starts in the rectum.
• If PC protection is lowest distally even in health, then any additional stress — dysbiosis, bacterial phospholipases, constipation/contact time, dairy/gluten trigger, oxidative stress, sleep/stress — may push rectal mucus below its protective threshold first.
• This directly strengthens the mucus PC/barrier node in the central theory.

Caveat:

• Much of the PC theory is associated with a specific research group and needs broader replication/formulation-specific caution.

5. Relative stasis and prolonged mucosal contact may matter in rectum/cecum/terminal ileum

Source: “The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics.” PMID: 11768558.

Key extracted abstract points:

• Luminal bacterial flora plays a major role in initiation/perpetuation of chronic IBD.
• Animal models show colitis does not occur in a germ-free environment.
• In human IBD, inflammation is present in parts of the gut containing the highest bacterial concentrations.
• The terminal ileum, cecum, and rectum are described as areas of relative stasis, providing prolonged mucosal contact with luminal contents.
• Enhanced mucosal permeability may help maintain chronic inflammation via bacterial/products contact.

Central-theory implication:

• This supports Paul’s stool-contact-time hypothesis.
• It also explains why Paul can have both rectal and sometimes cecal pain: both are anatomically plausible stasis/contact points.
• It integrates well with the sequence: mucus → constipation/retention → blood/pain.

6. Diversion colitis / short-chain fatty acids: the fecal stream is both fuel and irritant context

Sources:

• Glotzer et al. Gastroenterology 1981. “Proctitis and colitis following diversion of the fecal stream.” PMID: 7450438.
• “Diversion colitis: histological features in the colon and rectum after defunctioning colostomy.” Gut 1991. PMID: 1916483.
• Harig et al. New England Journal of Medicine 1989. “Treatment of diversion colitis with short-chain-fatty acid irrigation.” PMID: 2909876.
• “Effects of short-chain fatty acids on the inflamed colonic mucosa.” PMID: 9145448.

Key extracted points:

• Excluding a colon/rectal segment from the fecal stream can produce inflammation that resembles mild UC.
• Diversion colitis can cause rectal discharge of blood or mucus and histologic abnormalities.
• Reanastomosis can rapidly restore the excluded bowel toward normal in diversion colitis.
• One hypothesis is that absence of luminal SCFAs, especially butyrate, deprives colonocytes of preferred metabolic fuel.
• SCFA/butyrate enemas helped in initial diversion colitis reports, but later studies were not uniformly positive.
• In distal UC, impaired mucosal oxidation of SCFAs has been described despite luminal abundance.

Central-theory implication:

• This sharpens the model: fecal stream/luminal contents are not simply “bad.”
• The rectum needs the right luminal nutrients/metabolites for epithelial fuel, but can be damaged by the wrong microbes/metabolites/toxins when the barrier is weak.
• This fits Digest 001’s thiolase/butyrate oxidation finding: even if butyrate is present, UC colonocytes may not oxidize it normally under redox stress.

7. Distal metabolites can differ from proximal metabolites

Source: “Nicotine Oral Administration Attenuates DSS-Induced Colitis Through Upregulation of Indole in the Distal Colon and Rectum in Mice.” PMID: 34966763.

Key extracted points:

• In a mouse DSS colitis model, oral nicotine increased indole in feces.
• Indole increased in the distal colon and rectum but not cecum/proximal colon.
• DSS colitis severity was reduced clinically/histologically in the model.

Central-theory implication:

• This is not a recommendation to use nicotine or smoke.
• But it supports the idea that the distal colon/rectum has a distinct metabolite environment and that distal metabolites can influence colitis severity.
• It may partly relate to the long-observed smoking/nicotine paradox in UC, but nicotine has real cardiovascular/addiction risks and should remain a clinician-discussion/research node only.

Updated causal answer: why rectum first?

Current best explanation from this batch:

1. Anatomical/luminal exposure: the rectum is a storage/contact zone with high bacterial/luminal load and relative stasis.
2. Barrier vulnerability: the inner mucus barrier must keep bacteria away from epithelium; active UC shows this barrier becomes penetrable.
3. Phosphatidylcholine gradient: PC protection may thin toward the rectum, making the rectum the lowest-reserve mucus-barrier site.
4. Metabolic vulnerability: rectal/distal colon epithelial repair depends on SCFA/butyrate use, but UC may impair butyrate oxidation/redox handling.
5. Motility/contact amplification: constipation/incomplete evacuation increases contact time between stool/metabolites and a vulnerable distal mucosa.
6. Trigger stacking: dairy/gluten/stress/sleep loss/infection/dysbiosis may push the local system past threshold.

How this maps to Paul’s pattern

Paul’s pattern becomes more coherent under this model:

• Mucus first: barrier stress/goblet-cell/mucin response before overt bleeding.
• Constipation before blood: rectal inflammation or dysmotility increases retention/contact time, worsening local injury.
• Rectal pain: local epithelial exposure/inflammation and tenesmus/pelvic floor guarding.
• Cecal pain sometimes: cecum is also a relative stasis/high-contact site, so it may be a second vulnerable node.
• Dairy-triggered blood: still needs direct source digestion, but could be a fast trigger on a low-reserve barrier.
• Sleep/stress effect: likely reduces repair/barrier resilience and alters motility/autonomic tone.

What this supports / weakens in the central theory

Supports:

• Mucus PC/barrier node.
• Microbial contact/pathobiont node.
• Stool retention/contact-time node.
• Epithelial energy/redox node.
• Distal-first vulnerability rather than random immune attack.

Weakens:

• Any theory that ignores rectal anatomy and stool-contact physiology.
• Any theory that treats immune activation as sufficient explanation without explaining why the rectum starts first.

Still unresolved:

• Whether Paul’s specific disease is primarily PC depletion, dysbiosis/pathobiont, redox failure, food immune trigger, constipation/contact-time, or a stack of these.
• Whether topical/local barrier repair is more important than oral systemic intervention for proctitis.
• Whether fecal calprotectin, ALP, cholesterol, stool test data, diet exposure, and bowel form can be aligned into a repeatable causal timeline.

Clinician questions generated

• Is Paul’s disease always rectal/distal on scope, or has there been proximal extension/cecal patch/backwash ileitis?
• During flares, does inflammation visually/histologically correlate with mucus depletion/goblet-cell depletion?
• Would topical/local therapies aimed at the rectum make more mechanistic sense than oral-only strategies?
• Is constipation/incomplete evacuation/tenesmus present enough to treat as a flare amplifier?
• Are infection/STI/C. diff/CMV or medication-induced proctitis ever relevant based on episodes and testing history?
• Can the ALP/cholesterol/calprotectin pattern be lined up with bowel frequency, Bristol stool type, mucus, and dairy/gluten exposure?

Next source batch recommendation

Next digest should cover dairy/milk protein/gluten/wheat sensitivity and rectal bleeding/UC activity, because Paul’s rapid dairy → blood observation is one of the most personally important causal clues.